Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kazia Therapeutics Ltd KZIA

Healthcare Biotechnology
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor... see more

Recent & Breaking News (NDAQ:KZIA)

KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCE

PR Newswire January 25, 2022

KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE

PR Newswire January 7, 2022

KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER

PR Newswire December 13, 2021

Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma

PR Newswire December 4, 2021

GBM AGILE Opens to Paxalisib in Canada

PR Newswire November 29, 2021

Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

PR Newswire November 15, 2021

PNOC Study in Childhood Brain Cancer Enrols First Patient

PR Newswire November 11, 2021

Kazia Enrols First Patient to EVT801 Phase I Clinical Trial

PR Newswire November 4, 2021

Kazia TherapeuticsTrust (KZIA): Multiple Paxalisib Data Points Expected in Q4

Accesswire October 14, 2021

Kazia Therapeutics to Present at LD Micro Main Event

PR Newswire October 6, 2021

Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference

PR Newswire September 10, 2021

Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day

PR Newswire July 21, 2021

Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs

PR Newswire June 30, 2021

Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma

PR Newswire June 15, 2021

Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

PR Newswire June 7, 2021

Kazia Therapeutics to Present at LD Micro Invitational XI

PR Newswire June 3, 2021

Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis

Accesswire April 20, 2021

Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE

PR Newswire April 19, 2021

Kazia Therapeutics (KZIA): Paxalisib Chinese Rights Licensed

Accesswire March 30, 2021

Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company

Canada NewsWire March 29, 2021